Reata Pharmaceuticals, Inc. (RETA) has a consensus analyst rating of Hold, based on 10 analysts covering the stock. Of those, 4 recommend buying, 6 recommend holding, and 0 recommend selling.
The analyst consensus price target for RETA is $62.67, representing a -63.6% downside from the current price of $172.36. Price targets range from a low of $27.00 to a high of $115.00.
